12/9
08:19 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
12/9
08:19 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
12/9
08:13 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
12/9
08:13 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
12/9
06:41 am
srpt
Sarepta initiated with an Outperform at Wedbush
Low
Report
Sarepta initiated with an Outperform at Wedbush
12/9
06:41 am
srpt
Sarepta initiated with an Outperform at Wedbush
Low
Report
Sarepta initiated with an Outperform at Wedbush
11/5
12:51 pm
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/5
12:51 pm
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/5
10:27 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/5
10:27 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/5
10:16 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/5
10:16 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
11/5
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $26.00 price target on the stock.
High
Report
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $26.00 price target on the stock.
11/5
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $26.00 price target on the stock.
High
Report
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $26.00 price target on the stock.
11/5
06:01 am
srpt
Rating for SRPT
High
Report
Rating for SRPT
11/5
06:01 am
srpt
Rating for SRPT
High
Report
Rating for SRPT
11/5
04:43 am
srpt
Sarepta upgraded to Outperform from Neutral at Mizuho
High
Report
Sarepta upgraded to Outperform from Neutral at Mizuho
11/5
04:43 am
srpt
Sarepta upgraded to Outperform from Neutral at Mizuho
High
Report
Sarepta upgraded to Outperform from Neutral at Mizuho
11/4
12:21 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
11/4
12:21 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
9/22
08:08 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $50.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $50.00 price target on the stock.
9/22
07:19 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
9/22
07:19 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
9/22
05:09 am
srpt
Sarepta upgraded to Outperform from Market Perform at BMO Capital
Low
Report
Sarepta upgraded to Outperform from Market Perform at BMO Capital
9/22
05:09 am
srpt
Sarepta upgraded to Outperform from Market Perform at BMO Capital
Low
Report
Sarepta upgraded to Outperform from Market Perform at BMO Capital